No abstract

ClinicalTrials.gov identifier, NCT00991276; http://clinicaltrials.gov/show/NCT00991276.

No abstract

U ntil recently, the importance of aldosterone in the development of hypertension has been underestimated and the assumption made that aldosterone-mediated effects could be adequately controlled with angiotensin-converting enzyme (ACE) inhibitors or angiotensin-receptor blockers (ARBs). However, long-term ACE inhibitor or ARB therapy may not adequately protect patients from the effects of aldosterone escape [1][2][3] -an effect that can be minimized by blocking aldosterone at the mineralocorticoid receptor. 4A growing body of clinical evidence has linked aldosterone to the development of hypertension, cardiac hypertrophy, cardiac and vascular fibrosis,

Time to LTR was significantly longer with pregabalin CR versus placebo in fibromyalgia patients who initially showed improvement with pregabalin CR, indicating maintenance of response. Pregabalin CR was well tolerated in most patients. Generalizability may be limited by study duration and selective population.

No abstract

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

No abstract